Proc Natl Acad Sci 2008;105:18782-7
Lifestyle Support: Weight loss is not just about medication
Also at ObesityWeek, AstraZeneca presented early data for AZD6234, its long-acting amylin receptor agonist which, unlike most obesity therapies, targets the amylin pathway but is designed to achieve broadly similar effectsdelay gastric emptying, suppress appetite and promote the release of glucagon from the pancreas
And it starts with understanding your full picture
Below, we detail the evidence-based benefits of GHK-Cu, supported by peer-reviewed research, to demonstrate why its the ideal choice for formulators seeking to create cutting-edge, results-driven skincare solutions
The market for GLP-1-specific nutrition products is completely unserved, representing a $400M+ immediate opportunity within a broader $3B+ addressable market